### CURRICULUM VITAE of Prof. LU AIPING

#### Academic qualifications:

1978-1983: B. Med. Jiangxi University of Traditional Chinese Medicine, Nanchang, China1984-1987: M. Med. China Academy of Traditional Chinese Medicine, Beijing, China1994-1997: M.D. China Academy of Traditional Chinese Medicine, Beijing, China

#### Previous academic positions held:

- 1999-2002: Director, Institute of Basic Theory, China Academy of Chinese Medical Sciences
- 2002-2006: General Director, National Pharmaceutical Engineering Center for Solid Preparation in Chinese Herbal Medicine
- 2004-2009: Visiting Scholar, Hong Kong Poly-technology University
- 2006-2012: Deputy Director, Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences

#### **Present academic position:**

2012- Dean and Chair Professor, School of Chinese Medicine, Hong Kong Baptist University, China

#### Previous relevant research work:

- Technical expertise: Clinical evaluation and pharmacological evaluation on Traditional Chinese Medicine.
- Research area: Autoimmune disease, focusing on rheumatoid arthritis.

#### Section A: Five most representative publications in recent five years

- Fangfei Li, Jun Lu, Jin Liu, Chao Liang, Maolin Wang, Luyao Wang, Defang Li, Houzong Yao, Qiulong Zhang, Jia Wen, Zong-Kang Zhang, Jie Li, Quanxia Lv, Xiaojuan He, Baosheng Guo, Daogang Guan, Yuanyuan Yu, Lei Dang, Xiaohao Wu, Yongshu Li, Guofen Chen, Feng Jiang, Shiguo Sun, Bao-Ting Zhang, <u>Aiping Lu</u> (Corresponding <u>Author</u>), Ge Zhang, A water-soluble nucleolin aptamer-paclitaxel conjugate for tumorspecific targeting in ovarian cancer. *Nature Communications*, 2017. DOI: 10.1038/s41467-017-01565-6.
- 2. Defang Li, Jin Liu, Baosheng Guo, Chao Liang, Lei Dang, Cheng Lu, Xiaojuan He, Hilda Yeuk-Siu Cheung, Liang Xu, Changwei Lu, Bing He, Biao Liu, Atik Badshah Shaikh, Fangfei Li, Luyao Wang, Zhijun Yang, Doris Wai-Ting Au, Songlin Peng, Zongkang Zhang, Bao-Ting Zhang, Xiaohua Pan, Airong Qian, Peng Shang, Lianbo Xiao, Baohong Jiang, Chris Kong-Chu Wong, Jiake Xu, Zhaoxiang Bian, Zicai Liang, De-an Guo, Hailong Zhu, Weihong Tan, <u>Aiping Lu (Corresponding Author)</u> and Ge Zhang (Corresponding Author), Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation. *Nature Communication* 2016; 7: 10872

- Chao Liang, Baosheng Guo, Heng Wu, Ningsheng Shao, Defang Li, Jin Liu, Lei Dang, Cheng Wang, Hui Li, Shaohua Li, Wing Ki Lau, Yu Cao, Zhijun Yang, Cheng Lu, Xiaojuan He, D W T Au, Xiaohua Pan, Bao-Ting Zhang, Changwei Lu, Hongqi Zhang, Kinman Yue, Airong Qian, Peng Shang, Jiake Xu, Lianbo Xiao, Zhaoxiang Bian, Weihong Tan, Zicai Liang, Fuchu He, Lingqiang Zhang, <u>Aiping Lu (Corresponding Author)</u> and Ge Zhang (Corresponding Author), Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference–based bone anabolic strategy. *Nature Medicine* 2015, 21:288-94
- Hongyan Zhao, Jian Li, Xiaojuan He, Cheng Lu, Cheng Xiao, Xuyan Niu, Ning Zhao, Dahong Ju, and <u>Aiping Lu (Corresponding Author)</u>. The protective effect of yi shen juan bi pill in arthritic rats with castration-induced kidney deficiency. *Evid Based Complement Alternat Med*. 2012; 2012:102641.
- Cheng Lu, Xuyan Niu, Cheng Xiao, Gao Chen, Qinglin Zha, Hongtao Guo, Miao Jiang, and <u>Aiping Lu (Corresponding Author)</u>. Network-based gene expression biomarkers for cold and heat patterns of rheumatoid arthritis in traditional chinese medicine. *Evid Based Complement Alternat Med*. 2012; 2012:203043.

# Section B: Five representative publications beyond the recent five-year period with the latest publication entered first

- Xiaojuan He, Jun Shu, Li Xu, Cheng Lu and <u>Aiping Lu</u> (<u>Corresponding Author</u>). Inhibitory effect of Astragalus polysaccharides on lipopolysaccharide-induced TNF-a and IL-1β production in THP-1 cells. *Molecules*. 2012; 17(3):3155-3164.
- Jian Li, Yongheng Lu, Cheng Xiao, Cheng Lu, Xuyan Niu, Xiaojuan He, Hongyan Zhao, Yong Tan, <u>Aiping Lu (Corresponding Author)</u>. Comparison of toxic reaction of Tripterygium wilfordii multiglycoside in normal and adjuvant arthritic rats. J *Ethnopharmacol*. 2011; 135(2):270-277.
- Zhao H, Luo Y, Lu C, Lin N, Xiao C, Guan S, Guo DA, Liu Z, Ju D, He X, <u>Lu A</u> (<u>Corresponding Author</u>). Enteric mucosal immune response might trigger the immunomodulation activity of Ganoderma lucidum polysaccharide in mice. *Planta Med*. 2010;76(3):223-7.
- 4. Lu C, Zha Q, Chang A, He Y, <u>Lu A (Corresponding Author)</u>. Pattern differentiation in Traditional Chinese Medicine can help define specific indications for biomedical therapy in the treatment of rheumatoid arthritis. *J Altern Complement Med*. 2009;15(9):1021-5.
- Liu Z, Chao Z, Liu Y, Song Z, <u>Lu A (Corresponding Author)</u>. Maillard reaction involved in the steaming process of the root of Polygonum multiflorum. *Planta Med*. 2009;75(1):84-8.

#### Awards

- 1. National Science Fund for Distinguished Young Scholars (2008)
- 2. Ministry of Health Expert with Prominent Contribution (2002)

## **Funded Projects**

ID (Funding Body)	Title (Start-End, Project Fund)
HKBU 12122516 (GRF/RGC)	Does aberrantly overexpressed CKIP-1 suppress osteoblast-mediated articular bone repair in inflammatory arthritis? A collagen-induced non-human primate arthritis model (2017.1.1-2019.6.30, HK\$795,400)
HKBU 12102518 (GRF/RGC)	Toward the next generation of smart anti-tumor drugs: a highly water-soluble nucleolin aptamer- paclitaxel conjugate with a serum-stable linker for tumor-specific targeting in ovarian cancer (2019.1.1- 2021.6.30, HK\$697,734)
NSFC 81673773 (NSFC)	The role and molecular mechanism of obesity with Chinese medicine pattern of phlegm-dampness in the pathogenesis of hypertension (2017.1-2020.12, RMB590,000)
RC-IRMS/1314/3A-SCM (HKBU-RC)	Characterization of linkage between symbiotic gut microbes and fatty acid metabolism in rheumatoid arthritis patients (2014-2019.2.28, HK\$2,944,160)
RC-IRMS/16-17/03 (HKBU-RC)	The next generation aptamer screening system: a SMART, high yield, label-free and high throughput microfluidic platform (2018.04.01-2020.03.31)
SDF13-1209-P01 (HKBU-RC)	A Unique Platform for Drug Discovery of Combinational Drugs & Chinese Herbal Medicine / Compounds (2014-2017, HK\$3,000,000)
SDF15-0324-P02(b) (HKBU-RC)	Construction of Integrated Bioinformedicine & Translational Science Research (2015.8.15-2018.8.14, HK\$6,297,218)
SDF16-0603-P02 (HKBU-RC)	Strategic Development of Aptamer-based Drug Discovery Platform (2018.1.1-2019,12.31 HK\$5,000,000)
RC-ICRS/16-17/01 (HKBU- RC)	Toward precision medicine in aged osteoporotic subgroup with poor BMP responsiveness: Oligopeptide-chalcone derivative conjugate targeting osteoblasts for Smurf1 inhibition and bone formation enhancement (2018.01-2020.12, HK\$1,998,900)
Private Fund from Pian Zai Huang	Efficacy evaluation and mechanism exploration of Pien Tze Huang on multiple sclerosis (2015.7.30-2018.07.30, HK\$2,500,000)
Private Fund from Tai De	New drug R&D for therapeutic RNAi targeting CKIP-1 to reverse bone erosion in Rheumatology Arthritis (2015-2017, RMB3,000,000)